
Ruth Ann Vleugels

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1651460/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Drug-Associated Dermatomyositis Following Ipilimumab Therapy. JAMA Dermatology, 2015, 151, 195.	4.1	144
2	Anti-melanoma differentiation–associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features. Journal of the American Academy of Dermatology, 2018, 78, 776-785.	1.2	141
3	Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis. JAMA Dermatology, 2016, 152, 944.	4.1	114
4	Safety of Systemic Agents for the Treatment of Pediatric Psoriasis. JAMA Dermatology, 2017, 153, 1147.	4.1	75
5	A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. Rheumatology, 2021, 60, 2615-2628.	1.9	69
6	Eosinophilic Fasciitis: an Updated Review on Diagnosis and Treatment. Current Rheumatology Reports, 2017, 19, 74.	4.7	66
7	Cutaneous Dermatomyositis: An Updated Review of Treatment Options and Internal Associations. American Journal of Clinical Dermatology, 2013, 14, 291-313.	6.7	61
8	Epidemiology and Treatment of Eosinophilic Fasciitis. JAMA Dermatology, 2016, 152, 97.	4.1	60
9	Dermatomyositis: An Update on Diagnosis and Treatment. American Journal of Clinical Dermatology, 2020, 21, 339-353.	6.7	54
10	Treatment Options for Pityriasis Rubra Pilaris Including Biologic Agents. JAMA Dermatology, 2014, 150, 92.	4.1	51
11	A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria. JAMA Dermatology, 2020, 156, 270.	4.1	49
12	Dermatomyositis Induced by Anti–Tumor Necrosis Factor in a Patient With Juvenile Idiopathic Arthritis. JAMA Dermatology, 2013, 149, 1204.	4.1	40
13	Intravenous immunoglobulin for refractory cutaneous dermatomyositis: A retrospective analysis from an academic medical center. Journal of the American Academy of Dermatology, 2013, 69, 654-657.	1.2	37
14	Clinical Features and Comorbidities of Patients With Necrobiosis Lipoidica With or Without Diabetes. JAMA Dermatology, 2019, 155, 455.	4.1	36
15	A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents. JAMA Dermatology, 2020, 156, 384.	4.1	33
16	Management of cutaneous dermatomyositis. Dermatologic Therapy, 2012, 25, 112-134.	1.7	26
17	Characteristics and Alternative Treatment Outcomes of Antimalarial-Refractory Cutaneous Lupus Erythematosus. JAMA Dermatology, 2017, 153, 937.	4.1	25
18	Clinical Characteristics of Lupus Erythematosus Panniculitis/Profundus. JAMA Dermatology, 2020, 156, 1264.	4.1	24

RUTH ANN VLEUGELS

#	Article	IF	CITATIONS
19	Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea. JAMA Dermatology, 2020, 156, 521.	4.1	24
20	Epidemiology of concomitant psoriasis and hidradenitis suppurativa (HS): Experience of a tertiary medical center. Journal of the American Academy of Dermatology, 2015, 73, 701-702.	1.2	23
21	Augmented reality in dermatology: Are we ready for AR?. Journal of the American Academy of Dermatology, 2019, 81, 1216-1222.	1.2	22
22	Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers. JAMA Dermatology, 2019, 155, 494.	4.1	21
23	Palliative Therapy for Recalcitrant Cutaneous T-Cell Lymphoma of the Hands and Feet With Low-Dose, High Dose-Rate Brachytherapy. JAMA Dermatology, 2015, 151, 1354.	4.1	19
24	Sex and leadership in academic dermatology: A nationwide survey. Journal of the American Academy of Dermatology, 2017, 77, 782-784.	1.2	19
25	Clinicopathologic lessons in distinguishing cicatricial alopecia: 7 Cases of lichen planopilaris misdiagnosed as discoid lupus. Journal of the American Academy of Dermatology, 2014, 71, e135-e138.	1.2	17
26	Paraproteinemia-Associated Scleredema Treated Successfully With Intravenous Immunoglobulin. JAMA Dermatology, 2014, 150, 788.	4.1	17
27	Teledermatology Perception Differences Between Urban Primary Care Physicians and Dermatologists. JAMA Dermatology, 2015, 151, 339.	4.1	16
28	Segmental stiff skin syndrome (SSS): Two additional cases with a positive response to mycophenolate mofetil and physical therapy. Journal of the American Academy of Dermatology, 2016, 75, e237-e239.	1.2	16
29	Characteristics and treatment of adult-onset linear morphea: A retrospective cohort study of 61 patients at 3 tertiary care centers. Journal of the American Academy of Dermatology, 2016, 74, 577-579.	1.2	16
30	Characteristics and treatment of postirradiation morphea: A retrospective multicenter analysis. Journal of the American Academy of Dermatology, 2017, 76, 19-21.	1.2	16
31	Cutaneous Ulcerations in Anti-MDA5 Dermatomyositis. New England Journal of Medicine, 2019, 381, 465-465.	27.0	15
32	Tofacitinib as treatment for refractory dermatomyositis: A retrospective study from 2 academic medical centers. Journal of the American Academy of Dermatology, 2022, 86, 423-425.	1.2	15
33	Cutaneous dermatomyositis in the era of biologicals. Seminars in Immunopathology, 2016, 38, 113-121.	6.1	13
34	Pityriasis rubra pilaris: A study evaluating patient quality of life in 2 populations. Journal of the American Academy of Dermatology, 2019, 81, 638-640.	1.2	12
35	Thalidomide and lenalidomide for the treatment of refractory dermatologic conditions. Journal of the American Academy of Dermatology, 2016, 75, 210-212.	1.2	8
36	Strategies for effective medical student education in dermatology during the COVID-19 pandemic. Journal of the American Academy of Dermatology, 2021, 84, e33-e34.	1.2	7

RUTH ANN VLEUGELS

#	Article	IF	CITATIONS
37	Geographic distribution and environmental triggers of systemic sclerosis cases from 2 large academic tertiary centers in Massachusetts. Journal of the American Academy of Dermatology, 2022, 86, 925-927.	1.2	7
38	Dermatomyositis: current and future treatments. Expert Review of Dermatology, 2009, 4, 581-594.	0.3	6
39	Mycophenolate Mofetil for Eosinophilic Fasciitis. JAMA Dermatology, 2020, 156, 595.	4.1	6
40	Use of Tofacitinib, 2%, Ointment for Periorbital Discoid Lupus Erythematosus. JAMA Dermatology, 2021, 157, 880-882.	4.1	6
41	Treatment of Severe Multicentric Reticulohistiocytosis With Upadacitinib. JAMA Dermatology, 2021, 157, 735.	4.1	6
42	Immunologic underpinnings and treatment of morphea. Expert Review of Clinical Immunology, 2022, 18, 461-483.	3.0	6
43	Unilateral Gottron Papules in a Patient Following a Stroke. JAMA Dermatology, 2016, 152, 1062.	4.1	4
44	Sharps injuries among US dermatology trainees: A cross-sectional study. Journal of the American Academy of Dermatology, 2016, 74, 756-758.	1.2	4
45	Assessment of Antimalarial Therapy in Patients Who Are Hypersensitive to Hydroxychloroquine. JAMA Dermatology, 2019, 155, 491.	4.1	4
46	Challenges of securing insurance approval for oral tofacitinib for the treatment of alopecia areata: a multi-institution retrospective review. Archives of Dermatological Research, 2022, 314, 487-489.	1.9	4
47	Clinical features and eosinophilia in pityriasis rubra pilaris: A multicenter cohort. Journal of the American Academy of Dermatology, 2022, 86, 907-909.	1.2	4
48	Evaluating patient experience and satisfaction with teledermatology for isotretinoin management: a structured qualitative interview study. Journal of Dermatological Treatment, 2022, 33, 2698-2701.	2.2	4
49	Genetic diagnosis of immune dysregulation can lead to targeted therapy for interstitial lung disease: A case series and single center approach. Pediatric Pulmonology, 2022, 57, 1577-1587.	2.0	4
50	Pediatric Autoimmune Connective Tissue Diseases: An Update on Disease Characteristics, Associations, and Management. Current Dermatology Reports, 2013, 2, 216-229.	2.1	3
51	Multiple Tense Bullae Localized to the Right Breast in a Woman in Her Seventies. JAMA Dermatology, 2013, 149, 1427.	4.1	3
52	Facing Uncertainty. New England Journal of Medicine, 2019, 381, 2253-2259.	27.0	3
53	Capecitabine-Related Eruption Mimicking Dermatomyositis in 2 Patients With Metastatic Breast Cancer. JAMA Dermatology, 2020, 156, 103.	4.1	3
54	Practice gaps in the evaluation of systemic involvement in patients with cutaneous sarcoidosis presenting to a dermatologist: A retrospective review of 48 patients. Journal of the American Academy of Dermatology, 2021, 85, 794-796.	1.2	3

RUTH ANN VLEUGELS

#	Article	IF	CITATIONS
55	Increased risk of systemic and cardiac sarcoidosis in Black patients with cutaneous sarcoidosis. Journal of the American Academy of Dermatology, 2022, 86, 1178-1180.	1.2	3
56	Characteristics and treatment of silicone granulomas: A retrospective multicenter cohort of 21 patients. JAAD International, 2021, 3, 111-114.	2.2	3
57	Recognition and Management of Cutaneous Connective Tissue Diseases. Medical Clinics of North America, 2021, 105, 757-782.	2.5	3
58	Treatment With Mycophenolate Mofetil for Salt-and-Pepper Dyspigmentation Caused by Autoimmune Sclerosing Disease. JAMA Dermatology, 2022, 158, 327.	4.1	3
59	Approach to and Management of the Neutrophilic Dermatoses. Current Dermatology Reports, 2016, 5, 18-29.	2.1	2
60	Antimelanoma Differentiation-associated Gene 5 Dermatomyositis. Journal of Rheumatology, 2017, 44, 850-851.	2.0	2
61	Intravenous Immunoglobulin for Refractory Eosinophilic Fasciitis: A Retrospective Analysis from 3 Tertiary Care Centers. Journal of the American Academy of Dermatology, 2019, , .	1.2	2
62	Willingness-to-pay stated preferences in cutaneous lupus erythematosus: a pilot study. Archives of Dermatological Research, 2020, 312, 527-531.	1.9	2
63	Tense Bullae on the Palms and Soles. JAMA Dermatology, 2015, 151, 99.	4.1	1
64	Dermatology subspecialty clinic for patients with connective tissue disease impacts diagnosis and treatment: A single-center, retrospective analysis. Journal of the American Academy of Dermatology, 2021, 85, 476-478.	1.2	1
65	Lack of association between tumor necrosis factor-α inhibitor use and exacerbation of lupus erythematosus: A retrospective cohort study. Journal of the American Academy of Dermatology, 2021, ,	1.2	1
66	The catch-22 of limited Food and Drug Administration approval for connective tissue disease therapies. Journal of the American Academy of Dermatology, 2021, 85, 517-519.	1.2	1
67	Dermatology education in internal medicine residency programs: A nationwide survey of program directors. Journal of the American Academy of Dermatology, 2021, 85, 482-484.	1.2	1
68	Race and gender differences in systemic sclerosis: a retrospective multicenter cohort. International Journal of Dermatology, 2022, 61, .	1.0	1
69	Characteristics and Outcomes of Eosinophilic Fasciitis–Associated Monoclonal Gammopathy. JAMA Dermatology, 2021, , .	4.1	1
70	Crowdsourcing as a means of fundraising for juvenile dermatomyositis. Pediatric Dermatology, 2022, 39, 379-381.	0.9	1
71	Identifying When Therapy for One Skin Disease Is Likely to Exacerbate Another Skin Condition. Archives of Dermatology, 2011, 147, 836.	1.4	0
72	Porphyria Cutanea Tarda Masquerading as Systemic Sclerosis: Two Cases Demonstrating an Important Clinical Observation. Journal of Rheumatology, 2021, 48, 145-146.	2.0	0